Browse News
Filter News
Found 21 articles
-
ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023
2/26/2024
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) today reported financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on recent developments.
-
ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)
11/9/2022
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the FDA has approved the Investigational New Drug (IND) application to initiate a Phase II collaborative study with iadademstat in patients with relapsed/refractory high grade neuroendocrine carcinomas (NEC).
-
ORYZON Announces Oral Data Presentation at the Upcoming 64th American Society of Hematology Annual Conference
11/7/2022
Oryzon Genomics, S.A has been selected for oral presentation at the upcoming 64th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 10-13, 2022 in New Orleans.
-
ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2022CNS
11/2/2022
Oryzon Genomics, S.A. reported financial results for the third quarter of 2022 and provided an update on recent developments.
-
ORYZON to Give Updates on Corporate Progress in October
10/3/2022
Oryzon Genomics, S.A. announced today that its management will give an update on corporate progress at several international events in October.
-
ORYZON to Give Updates on Corporate Progress in September 2022
9/8/2022
Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced that its management will give an update on corporate progress at several international events in September.
-
ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022
7/22/2022
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first half of 2022 and provided an update on recent developments.
-
ORYZON at EHA-2022: Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML
6/10/2022
Oryzon Genomics, S.A. today presents new positive efficacy data from its ongoing Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML).
-
ORYZON to Give Updates on Corporate Progress in June 2022
6/6/2022
Oryzon Genomics, S.A. announced that its management will give an update on corporate progress at several international events in June.
-
ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2022
5/5/2022
Oryzon Genomics, S.A. reported financial results for the first quarter of 2022 and provided an update on recent developments.
-
ORYZON Reports Results and Corporate Update for Q4 and Year Ended December 31, 2021
2/7/2022
Oryzon Genomics, S.A. today reported financial results for the fourth quarter of 2021 and provided an update on recent developments.
-
ORYZON at ASH-2021: Iadademstat 36-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML
12/13/2021
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), today presents new positive efficacy data from its ongoing Phase IIa ALICE trial, investigating iadademstat in combination with azacitidine in elderly or unfit patients with acute myeloid leukemia (AML), at the 63rd American Society of Hematology Annual Conference, ASH-2021.
-
ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2021
10/28/2021
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the third quarter of 2021 and provided an update on recent developments.
-
ORYZON Presents Iadademstat ALICE 30-Month Data at EHA-2021, Confirming Positive and Robust Efficacy in Combination with Azacitidine in AML
6/11/2021
Oryzon Genomics, S.A.presented today new positive efficacy data from its ongoing Phase IIa ALICE trial.
-
ORYZON to Present New Clinical Data and Corporate Updates at International Conferences in May and June
5/13/2021
BioEquity Europe Digital Oxford Global’s Online Drug Discovery Week Jefferies Virtual Healthcare Conference 2021 Precision in Drug Discovery & Preclinical Virtual Summit European Hematology Association (EHA) 2021 Congress BIO International Convention 2021
-
ORYZON Presents New Robust Phase II Iadademstat Efficacy Data in AML at ASH-2020
12/7/2020
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, presents new positive efficacy data from its ongoing Phase II ALICE trial, which is investigating iadademstat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML)
-
ORYZON First Half Ended June 30, 2020 Results and Corporate Update
7/22/2020
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first half of 2020 and provided an update on recent developments.
-
Clinical Catch-Up: June 8-12
6/15/2020
It was a fairly busy week with clinical trial updates and announcements. Here’s a look. -
ORYZON Presents New Phase II Iadademstat Efficacy Data in AML at EHA-2020
6/12/2020
Robust signals of clinical efficacy, with ORR of 77%, of which 60% are CR/CRi Fast clinical responses, with mean time to response of 37 days Longest remission to date 488 days, still ongoing Iadademstat and azacitidine combination shows a good safety profile Results presented at 25th Congress of the European Hematology Association MADRID, Spain and CAMBRIDGE, Mass., June 12, 2020 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinica
-
ORYZON First Quarter 2020 Results and Corporate Update
5/11/2020
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today reported financial results for the first quarter of 2020 and provided an update on recent developments.